Journal of Experimental Medicine, Vol 175, 217-225, Copyright © 1992 by Rockefeller University Press

ARTICLES

Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene

MR Shalaby, HM Shepard, L Presta, ML Rodrigues, PC Beverley, M Feldmann and P Carter
Department of Cell Biology, Genentech, Inc., South San Francisco, California 94080.

The HER2 protooncogene encodes a 185-kD transmembrane phosphoglycoproteins, human epidermal growth factor receptor 2 (p185HER2), whose amplified expression on the cell surface can lead to malignant transformation. Overexpression of HER2/p185HER2 is strongly correlated with progression of human ovarian and breast carcinomas. Recent studies have shown that human T cells can be targeted with bispecific antibody to react against human tumor cells in vitro. We have developed a bispecific F(ab')2 antibody molecule consisting of a humanized arm with a specificity to p185HER2 linked to another arm derived from a murine anti-CD3 monoclonal antibody that we have cloned from UCHT1 hybridoma. The antigen-binding loops for the anti-CD3 were installed in the context of human variable region framework residues, thus forming a fully humanized BsF(ab')2 fragment. Additional variants were produced by replacement of amino acid residues located in light chain complementarity determining region 2 and heavy chain framework region 3 of the humanized anti-CD3 arm. Flow cytometry analysis showed that the bispecific F(ab')2 molecules can bind specifically to cells overexpressing p185HER2 and to normal human peripheral blood mononuclear cells bearing the CD3 surface marker. In additional experiments, the presence of bispecific F(ab')2 caused up to fourfold enhancement in the cytotoxic activities of human T cells against tumor cells overexpressing p185HER2 as determined by a 51Cr release assay. These bispecific molecules have a potential use as therapeutic agents for the treatment of cancer.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Serebrovskaya, E. O., Edelweiss, E. F., Stremovskiy, O. A., Lukyanov, K. A., Chudakov, D. M., Deyev, S. M. (2009). Targeting cancer cells by using an antireceptor antibody-photosensitizer fusion protein. Proc. Natl. Acad. Sci. USA 106: 9221-9225 [Abstract] [Full Text]  
• Chen, Y.-P., Qiao, Y.-Y., Zhao, X.-H., Chen, H.-S., Wang, Y., Wang, Z. (2007). Rapid Detection of Hepatitis B Virus Surface Antigen by an Agglutination Assay Mediated by a Bispecific Diabody against Both Human Erythrocytes and Hepatitis B Virus Surface Antigen. CVI 14: 720-725 [Abstract] [Full Text]  
• Chan, J. K., Hamilton, C. A., Cheung, M. K., Karimi, M., Baker, J., Gall, J. M., Schulz, S., Thorne, S. H., Teng, N. N., Contag, C. H., Lum, L. G., Negrin, R. S. (2006). Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.. Clin. Cancer Res. 12: 1859-1867 [Abstract] [Full Text]  
• Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., Karami, M., Cao, Y.-a., Marina, N., Contag, C. H., Negrin, R. S. (2005). Low Levels of Her2/neu Expressed by Ewing's Family Tumor Cell Lines Can Redirect Cytokine-Induced Killer Cells. Clin. Cancer Res. 11: 4561-4570 [Abstract] [Full Text]  
• Schlapschy, M., Gruber, H., Gresch, O., Schafer, C., Renner, C., Pfreundschuh, M., Skerra, A. (2004). Functional humanization of an anti-CD30 Fab fragment for the immunotherapy of Hodgkin's lymphoma using an in vitro evolution approach. Protein Eng Des Sel 17: 847-860 [Abstract] [Full Text]  
• Smith, K A, Nelson, P N, Warren, P, Astley, S J, Murray, P G, Greenman, J (2004). Demystified...recombinant antibodies.. J. Clin. Pathol. 57: 912-917 [Abstract] [Full Text]  
• Le Gall, F., Reusch, U., Little, M., Kipriyanov, S. M. (2004). Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 17: 357-366 [Abstract] [Full Text]  
• Scheffold, C., Kornacker, M., Scheffold, Y. C., Contag, C. H., Negrin, R. S. (2002). Visualization of Effective Tumor Targeting by CD8+ Natural Killer T Cells Redirected with Bispecific Antibody F(ab')2HER2xCD3. Cancer Res. 62: 5785-5791 [Abstract] [Full Text]  
• Carpenter, P. A., Pavlovic, S., Tso, J. Y., Press, O. W., Gooley, T., Yu, X.-Z., Anasetti, C. (2000). Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells. J. Immunol. 165: 6205-6213 [Abstract] [Full Text]  
• Milgrom, H., Fick, R. B., Su, J. Q., Reimann, J. D., Bush, R. K., Watrous, M. L., Metzger, W. J., The rhuMAb-E25 Study Group, (1999). Treatment of Allergic Asthma with Monoclonal Anti-IgE Antibody. NEJM 341: 1966-1973 [Abstract] [Full Text]  
• Shan, D., Press, O. W., Tsu, T. T., Hayden, M. S., Ledbetter, J. A. (1999). Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths. J. Immunol. 162: 6589-6595 [Abstract] [Full Text]  
• Baca, M., Presta, L. G., O'Connor, S. J., Wells, J. A. (1997). Antibody Humanization Using Monovalent Phage Display. J. Biol. Chem. 272: 10678-10684 [Abstract] [Full Text]  
• Thompson, J., Hu, H., Scharff, J., Neville, D. M. Jr. (1995). An Anti-CD3 Single-chain Immunotoxin with a Truncated Diphtheria Toxin Avoids Inhibition by Pre-existing Antibodies in Human Blood. J. Biol. Chem. 270: 28037-28041 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS